Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Caryn Garriga

Pediatrics Ellisville, MO Medical Doctor

NPI 1366583122 CMS profile 243119

249 Clarkson Rd, Suite 102, Ellisville, MO 63011

Open in the dashboard

General payments

$4,148

268 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Caryn Garriga of Ellisville, MO is reported in the CMS Open Payments database as having received $4,148 across 268 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $436 25
2024 General $526 30
2023 General $726 45
2022 General $997 58
2021 General $713 55
2020 General $295 21
2019 General $455 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Caryn Garriga
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Caryn Garriga were reported at $436. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Caryn Garriga Pediatrics median Middle half National median
2019 $455 $86 $31–$183 $163
2020 $295 $49 $22–$110 $114
2021 $713 $68 $27–$158 $132
2022 $997 $77 $30–$173 $149
2023 $726 $88 $33–$190 $160
2024 $526 $94 $34–$206 $164
2025 $436 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neos Therapeutics, LP $1,747 110 payments
  2. Corium, Inc. $505 33 payments
  3. Tris Pharma Inc $484 34 payments
  4. Ironshore Pharmaceuticals Inc. $418 26 payments
  5. Supernus Pharmaceuticals, Inc. $396 24 payments
  6. Vertical Pharmaceuticals, LLC $114 7 payments
  7. Adlon Therapeutics L.P. $74 6 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $68 4 payments
  9. Collegium Pharmaceutical, Inc. $59 3 payments
  10. Arbor Pharmaceuticals, Inc. $54 4 payments
  11. Other $230 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,128 266 payments
  2. Education $21 2 payments
Products named General payments · program years 2019–2025
  1. Adzenys XR-ODT Adhd $1,406 88 payments
  2. Azstarys $505 33 payments
  3. COTEMPLA XR-ODT $416 31 payments
  4. QELBREE $302 19 payments
  5. JORNAY PM Central Nervous Stimulant ADHD $228 16 payments
  6. Adzenys XR-ODT Adhd $185 16 payments
  7. Quillivant XR $177 14 payments
  8. Dyanavel XR Adhd $134 8 payments
  9. JORNAY PM Central Nervous System Stimulant $107 6 payments
  10. Dyanavel XR Adhd $96 7 payments
  11. Other $959 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

268 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record